Clinical trial · Observational
Cost Effectiveness Of Sunitinib In Central America And Caribbean
Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean
NCT01033981CI-TRIAL-00006736terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): See termination reason in detailed description.
Summary
Brief summary (as posted)
Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America and Caribbean countries
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Central America and Caribbean
- description
- Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad \& Tobago
- interventionNames
- Drug: Sunitinib
Primary outcomes (5)
- measure
- Rate of patients that present metastasis when consulting for first time
- timeFrame
- 9 months
- measure
- Rate of use of Sutent, IFN-α and Bevacizumab + IFN-α as first-line treatment
- timeFrame
- 9 months
- measure
- Hospitalization average with Sutent, with IFN-α, and with Bevacizumab + IFN-α
- timeFrame
- 9 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Evidence of a personally signed (or legally acceptable representative) and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * Adult (18 years old or older) men and women with confirmed diagnosis of mRCC treated with Sutent, IFN-α or Bevacizumab + IFN ; on the selected institutions. Exclusion Criteria: * Adult men or women with RCCm treated with any other medication that is not Sutent, IFN-α or Bevacizumab + IFN. * Adult men or women with mRCC with palliative care. * Adult men or women with RCC without metastasis.
References
Publications (0)
Data not yet available
No reference posted for this study.